Abstract
Chemical xenogenization occurs when experimental tumors, treated in vivo or in vitro with selected chemicals, become immunogenic, i.e., able to induce a strong rejection response, immunological in nature, in the histocompatible hosts. Unlike modifications induced by haptens, changes in tumor cell immunogenicity associated with chemical xenogenization are heritable as a result of drug interfence with the genetic code. Drugs endowed with potent mutagenic activity are known to be powerful xenogenizing agents, and their mechanism of action is traditionally regarded as involving changes in DNA nucleotide sequence. Triazene and nitrosoguanidini derivatives are among the best known examples of this type of compound, and a large body of information has been accumulated over the years regarding the immunogenic properties of the tumor variants obtained following treatment with those xenogenizing agents. The present paper reviews this information, and also discusses the therapeutic implications of xenogenization in experimental systems of tumor immunotherapy. Xenogenization of murine tumors has also been obtained by means of chemicals devoid of mutagenic activity but capable of affecting gene transcriptional activity. The characteristics of this ‘new’ type of xenogenization are also reviewed and compared to those of triazene xenogenization.
Article PDF
Similar content being viewed by others
References
Foulds L: Neoplastic Development. Academic Press, New York, 1975
Poste G, Greig R: On the genesis and regulation of cellular heterogeneity in malignant tumors. Invasion Metastasis 2: 137–176, 1982
Hamburg VP, Svet-Moldavsky GI: Artificial heterogenization of tumors by means of herpes simplex and polyoma virus. Nature (Lond) 203: 772–773, 1964
Lindemann J, Klein PA: Viral oncolysis: increased immunogenicity of tumor cell antigen associated with influenza virus. J Exp Med 126: 93–108, 1967
Sjoegren HO, Hellstroem I: In vivo and in vitro demonstration of the polyoma specific transplantation antigen induced in polyoma infected Moloney lymphoma cells. Spec Tumor Antigens 2: 162–171, 1967
Kobayashi II, Kodama T, Shirai T, Kaji H, Hosokawa M, Sendo F, Saito II, Takeichi N: Artificial regression of rat tumors infected with Friend virus (xenogenization): an effect produced by acquired antigen. Hokkaido J Med Sci 44: 133–134, 1969
Austin FC, Boone CW: Virus augmentation of antigenicity of tumor cell extracts. Adv Cancer Res 30: 301–345, 1983
Heicappel R, Schirrmacher V, von Hoegen P, Ahlert T, Appelhans B: Prevention of metastatic spread by post-operative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int J Cancer 37: 569–577, 1986
Currie GA, Bagshawe KD: Tumor specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase. Br J Cancer 23: 141–149, 1969
Bekesi JG, St Arneault G, Walter L, Holland GF: Immunogenicity of leukemia L1210 cells after neuraminidase treatment. J Natl Cancer Inst 49: 107–118, 1972
Sethi KK, Brandis H: Neuraminidase induced loss in the transplantability of murine leukaemia L1210. Induction of immunoprotection and transfer of the induced immunity to normal DBA/2 mice by serum and peritoneal cells. Br J Cancer 27: 106–112, 1973
WatkinsJr E: Neuraminidase accentuation of cancer cell immunogenicity. Behring Inst Mitt 55: 355–369, 1974
Rios A, Simmons R: Active specific immunotherapy of minimal residual cells: excision plus neuraminidase-treated cells. Int J Cancer 13: 71–81, 1974
Nagamatsu Y: Studies on active immunization of mice with mitomycin and toyomycin-prepared Ehrlich ascites carcinoma tissue. Archs Jap Chir 33: 753–757, 1964
Galili N, Naor D, Asjao B, Klein G: Induction of immune responsiveness in a genetically low-response tumor-host combination by chemical modification of the immunogen. Eur J Immunol 6: 473–476, 1976
Benjamini E, Fong S, Erickson C, Leung CY, Rennick D, Scibiensky RJ. Immunity to lymphoid tumors induced in syngeneic mice by immunization with mitomycin C-treated cells. J Immunol 118: 685–693, 1977
Mihich E: Modifications of tumor regression by immunological means. Cancer Res 29: 2345–2350, 1969
Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A: Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc Nat Acad Sci (Wash) 66: 1066–1074, 1970
Nicolin A, Vadlamudi S, Goldin A: Antigenicity of L1210 leukemic sublines induced by drugs. Cancer Res 32: 653–657, 1972
Tsukagoshi S, Hashimoto Y: Increased immunosensitivity in nitrogen mustard-resistant Yoshida sarcoma. Cancer Res 33: 367–374, 1973
Koyama K, Ishii K: Induction of non-transplantable mutant clones from an ascites tumor. Gann 60: 367–374, 1969
Boon T, Kellermann O: Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci USA 74: 272–275, 1977
Frost P, Kerbel R, Bauer E, Tartamella-Biondo R, Cefalu W: Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res 43: 125–132, 1983
Shinizky M, Skornick Y, Haran-Ghera N: Effective tumor immunization induced by cells of elevated membrane-lipid microviscosity. Proc Natl Acad Sci USA 76: 5313–5316, 1979
Klein G, Klein E: Induction of tumor cell rejection in the low responsive YAC-lymphoma strain A host combination by immunization with somatic cell hybrids. Eur J Cancer 15: 551–557, 1979
Kripke ML: Immunologic mechanism in UV radiation carcinogenesis. Adv Cancer Res 34: 69–103, 1981
Peppoloni S, Herberman RB, Gorelik E: Induction of highly immunogenic tumor variants of Lewis lung carcinoma tumor by ultraviolet irradiation. Cancer Res 45: 2560–2566, 1985
Frost P, Liteplo RB; Donaghue TP, Kerbel RS: Selection of strongly immunogenic ‘tum-’ variants from tumors at high frequency using 5-azacytidine. J Exp Med 159: 1491–1501, 1984
Kobayashi H: Viral xenogenization of intact tumor cells. Adv Cancer Res 30: 279–299, 1979
Fioretti MC, Bianchi R, Romani L, Bonmassar E: Drug-induced immunogenic changes of murine leukemic cells: dissociation of onset of resistance and emergence of novel immunogenicity. J Natl Cancer Inst 71: 1247–1251, 1983
Puccetti P, Romani L, Fioretti MC: Chemical xenogenization of tumor cells. Trends Pharmacol Sci 6: 485–487, 1985
Fioretti MC, Nardelli B, Bianchi R, Nisi C, Sava G: Antigenic changes of a murine lymphoma by in vivo treatment with triazene derivatives. Cancer Immunol Immunother 11: 283–286, 1981
Campanile F, Crinò L, Bonmassar E, Houchens D, Goldin A: Radioresistant inhibition of lymphoma growth in congenitally athymic (nude) mice. Cancer Res 37: 394–398, 1977
Connors TA, Goddard PM, Merai K, Ross WCJ, Wilman DEV: Tumour inhibitory triazenes: structural requirements for an active metabolite. Biochem Pharmacol 25: 241–246, 1976
Nardelli B, Contessa AR, Romani L, Sava G, Nisi C, Fioretti MC: Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene-derivatives. Cancer Immunol Immunother 16: 157–161, 1984
Nicolin A, Vadlamudi S, Goldin A: Increased immunogenicity of murine lymphatic tumors by pyrazole-4-carboxamide, 3 (or 5)-amino (NSC-1402; PGA). Cancer Chemother 57: 3–10, 1973
Riccardi C, Fioretti MC, Giampictri A, Puccetti P, Goldin A: Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo. Transplantation 25: 63–68, 1978
Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A: Antigenic changes of L1210 leukemia in mice treated with 5-(3–3′-dimethyl-1-triazeno)imidazole-4-carboxamide. Cancer Res 32: 1446–1450, 1972
Bonmassar E, Fioretti MC, Nicolin A, Spreafico F: Drug-induced modifications of tumor cell antigenicity. In: Spreafico F, Arnon R (eds) Tumor associated antigens and their specific immune response. Academic Press, London, New York, San Francisco, 1979, pp 251–270
Contessa AR, Bonmassar A, Giampietri A, Circolo A, Goldin A, Fioretti MC: In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3–3′-dimethyl-1-triazeno)imidazole-4-carboxamide. Cancer Res 41: 2476–2482, 1981
Campanile F, Houchens DP, Gaston M, Goldin A, Bonmassar E: Increased immunogenicity of two lymphoma lines after drug treatment of athymic (nude) mice. J Natl Cancer Inst 55: 207–209, 1975
Nicolin A, Spreafico F, Bonmassar E, Goldin A: Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide in vivo. J Natl Cancer Inst 56: 89–93, 1976
Romani L, Bianchi R, Puccetti P, Fioretti MC: Systemic adoptive immunotherapy of a highly immunogenic murine lymphoma growing in the brain. Int J Cancer 31: 477–482, 1983
Romani L, Nardelli B, Bianchi R, Puccetti P, Mage M, Fioretti MC: Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations. Int J Cancer 35: 659–665, 1985
Bianchi R, Romani L, Puccetti P, Fioretti MC: Inhibition of murine lymphoma growth by adoptive transfer of lymphocytes sensitized to a xenogenized tumor variant. Int J Cancer, 1987, in press
Contessa AR, Giampietri A, Bonmassar A, Goldin A: Increased immunogenicity of L1210 leukemia following short-term exposure to 5(3,3′-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vivo or in vitro. Cancer Immunol Immunother 7: 71–76, 1979
Houchens DP, Bonmassar E, Gaston MR, Kende M, Goldin A: Drug-mediated immunogenic changes of virus-induced leukemia in vivo. Cancer Res 36: 1347–1352, 1976
Romani L, Fioretti MC, Bonmassar E: In vitro generation of primary cytotoxic lymphocytes against L5178Y lcukemia antigenically alterated by 5-(3,3′-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo. Transplantation 28: 218–222, 1979
Nicolin A, Bini A, Coronetti E, Goldin A: Cellular immune response to a drug treated L5178Y lymphoma subline. Nature 251: 654–655, 1974
Santoni A, Kinney Y, Goldin A: Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug treatment in vivo. J Natl Cancer Inst 60: 109–112, 1978
Fioretti MC, Romani L, Taramelli D, Goldin A: Antigenic properties of lymphoma sublines derived from a drug-treated immunogenic L5178Y leukemia. Transplantation 26: 449–451, 1978
Taramelli D, Romani L, Bonmassar A, Goldin A, Fioretti MC: Expression of normal histocompatibility antigens in murine lymphomas treated with 5(3,3′-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) in vivo. Europ J Cancer 17: 411–420, 1981
Romani L, Puccetti P, Fioretti MC, Mage MG: Humoral response against murine lymphoma cells xenogenized by drug treatment in vivo. Int J Cancer 36: 225–231, 1985
Testorelli C, Archetti YL, Aresca P, Del Vecchio L: Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline. Cancer Res 45: 5299–5303, 1985
Fioretti MC, Romani L, Bonmassar A, Taramelli D: Appearance of strong transplantation antigens in non-immunogenic lymphoma following drug treatment in vivo. J Immunopharmacol 2: 189–212, 1980
Nicolin A, Franco P, Testorelli C, Goldin A: Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells. Cancer Res 36: 222–227, 1976
Felsenfeld G, McGhee J: Methylation and gene control. Nature 296: 602–603, 1982
Razin A, Riggs AC: DNA methylation and gene function. Science 210: 604–610, 1980
Puccetti P, Romani L, Allegrucci M, Dominici P, Borri-Voltattorni C, Fioretti MC: DNA methylating activity in murine lymphoma cells treated with xenogenizing chemicals. Cancer Detect Prevent, 1987, in press
Giampietri A, Fioretti MC, Goldin A, Bonmassar E: Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of quinacrine, an antimutagenic compound. J Natl Cancer Inst 64: 297–301, 1980
Boon T: Antigenic tumor cell variants obtained with mutagens. Adv Cancer Res 39: 121–151, 1983
Suzuki Y, Suzuki K, Hosokawa M, Kobayashi H: Immunogenicity of viable tumor cells. A comparison of xenogenized tumor cells and BCG-tumor cell mixtures. Cancer Immunol Immunother 22: 204–210, 1986
Puccetti P, Giampietri A, Fioretti MC: Long-term depression of two primary immune responses induced by a single dose of 5-(3,3′-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). Experientia 34: 799–800, 1978
Giampietri A, Bonmassar A, Puccetti P, Circolo A, Goldin A, Bonmassar E: Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy. Cancer Res 41: 681–687, 1981
Nardelli B, Puccetti P, Romani L, Sava G, Bonmassar E, Fioretti MC: Chemical xenogenization of murine lymphoma cells with triazenc derivatives: immunotoxicological studies. Cancer Immunol Immunother 17: 213–217, 1984
Romani L, Fioretti MC, Bianchi R, Nardelli B, Bonmassar E: Intracerebral adoptive immunotherapy of a murine lymphoma antigenically altered by drug treatment in vivo. J Natl Cancer Inst 68: 817–822, 1982
Boon T, Maryanski J: Tumour cell variants with increased immunogenicity obtained by mutagen treatment. Cancer Surveys 4: 135–148, 1985
Boon T, Van Pel A, Warnier G: Mouse teratocarcinoma cell variants obtained by mutagenesis: rejection by syngencic mice and immunization against the original tumor cell line. In: Peeters H (ed) Protides of Biological Fluids. Pergamon Press, Oxford, 1979, pp 173–177
Boon T, Kellermann O, Mathy E, Gaillard J: Mutagenized clones of a pluripotent teratoma cell line: variants with decreased differentiation or tumor-formation ability. In: Sherman MI, Solfer D (eds) Teratomas and Differentiation. Academic Press, New York, 1975, pp 161–166
Van Pel A, Georlette M, Boon T: Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngencic mice. Proc Natl Acad Sci USA 76: 5282–5285, 1979
Uyttenhove C, Van Snick J, Boon T: Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J Exp Med 152: 1175–1183, 1980
Van Pel A, Vessicre F, Boon T: Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J Exp Med 157: 1992–2001, 1983
Van Pel A, Boon T: Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 79: 4718–4722, 1982
Marchand M, Caspar P, Boon T: Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815. Eur J Cancer 19: 1529–1537, 1983
Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M: Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med 152: 1184–1193, 1980
Maryanski J, Van Snick J, Cerottini JC, Boon T: Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol 12: 401–406, 1982
Boon T: Tum variants: immunogenic variants obtained by mutagen treatment of tumor cells. Immunol Today 10: 307–311, 1985
Boon T, Van Pel A: Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci USA 75: 1519–1523, 1978
Georlette M, Boon T: Immunogenic cell variants of a mouse teratocarcinoma confer a protection against the original non-immunogenic transplantable tumor. Eur J Cancer 17: 1083–1087, 1981
Gorelik E, Peppoloni S, Overton R, Herberman RB: Increase in H-2 antigen expression and immunogenicity of BL6 melanoma cells treated with N-methyl-N-nitrosoguanidine. Cancer Res 45: 5341–5347, 1985
Altevogt P: Effects of mutagens on the immunogenicity of murine tumor cells: comparison of cell surface changes induced by 5-azacytidine and N-methyl-N′-nitrosoguanidine. Cancer Res 46: 2912–2916, 1986
Frost P, Kerbel RS: On the possible cpigenetic mechanism(s) of tumor cell heterogencity. The role of DNA methylation. Cancer Metast Rev 2: 375–378, 1983
Kerbel RS, Frost P, Liteplo R, Carlow DA, Elliott BE: Possible cpigenetic mechanisms of tumor progression: induction of high frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor-cell populations by 5-azacytidine treatment. J Cell Physiol S3: 87–97, 1984
Olsson L, Forchhammer J: Induction of the metastatic phenotype in a mouse tumor model by 5-azacytidine, and charaterization of an antigen associated with metastatic activity. Proc Natl Acad Sci USA 81: 3389–3393, 1984
Trainer DL, Kline T, Mallon F, Greig R, Poste G: Effect of 5-azacytidine on DNA methylation and the malignant properties of B16 melanoma cells. Cancer Res 45: 6124–6130. 1985
Ware JL, Lieberman AP, Webb KS: Metastatic phenotype of human prostate tumor cells in athymic nude mice: Alteration by exposure to ethyl methanesulfonate and ‘Reversion’ by 5-azacytidine. Cancer Immunol Immunother 21: 58–62, 1986
Schirrmacher V: Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies. Adv Cancer Res 43: 1–73, 1985
Carlow DA, Kerbel RS, Feltis JT, Elliott BE: Enhanced expression of class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma. J Natl Cancer Inst 75: 291–301, 1985
Puccetti P, Romani L, Dominici P, Tancini B, Fioretti MC: Studies on gene regulation of lymphoma cells chemically xenogenized by triazene derivatives (abstract). Cancer Detect Prevent 8: 547, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Puccetti, P., Romani, L. & Fioretti, M.C. Chemical xenogenization of experimental tumors. Cancer Metast Rev 6, 93–111 (1987). https://doi.org/10.1007/BF00052845
Issue Date:
DOI: https://doi.org/10.1007/BF00052845